{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.4","upperLimit":"11.1","value":"2.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"78"}],"units":"Participants"}],"description":"TTR assessed by the independent radiological review committee (IRRC) according to Criteria for Response Assessment of Lymphoma: Lugano 2014 Classification","dispersionType":"Full Range","groups":[{"description":"Participants received sugemalimab (CS1001) 1200 mg intravenously every 3 weeks (Q3W)","id":"OG000","title":"R/R ENKTL"}],"paramType":"MEDIAN","populationDescription":"Two patients were excluded from analysis: one patient was not confirmed as ENKTL by central pathology, and the other patient was identified as having no measurable or evaluable disease at baseline by IRRC.","reportingStatus":"POSTED","timeFrame":"From enrollment to end of follow-up, a median of 29 months","title":"Time to Response (TTR) Assessed by IRRC","type":"SECONDARY","unitOfMeasure":"months"}